134 related articles for article (PubMed ID: 38570079)
1. Restricted Net Treatment Benefit in oncology.
Piffoux M; Ozenne B; De Backer M; Buyse M; Chiem JC; Péron J
J Clin Epidemiol; 2024 Jun; 170():111340. PubMed ID: 38570079
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
Fukuda M; Sakamaki K; Oba K
Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
[TBL] [Abstract][Full Text] [Related]
4. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
5. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
[TBL] [Abstract][Full Text] [Related]
6. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.
Péron J; Roy P; Ozenne B; Roche L; Buyse M
JAMA Oncol; 2016 Jul; 2(7):901-5. PubMed ID: 27124210
[TBL] [Abstract][Full Text] [Related]
7. A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons.
Cantagallo E; De Backer M; Kicinski M; Ozenne B; Collette L; Legrand C; Buyse M; Péron J
Biom J; 2021 Feb; 63(2):272-288. PubMed ID: 32939818
[TBL] [Abstract][Full Text] [Related]
8. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
Latimer NR; Abrams KR; Siebert U
BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
[TBL] [Abstract][Full Text] [Related]
9. The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.
Dong G; Huang B; Chang YW; Seifu Y; Song J; Hoaglin DC
Pharm Stat; 2020 May; 19(3):168-177. PubMed ID: 31671481
[TBL] [Abstract][Full Text] [Related]
10. Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit.
Péron J; Lambert A; Munier S; Ozenne B; Giai J; Roy P; Dalle S; Machingura A; Maucort-Boulch D; Buyse M
J Natl Cancer Inst; 2019 Nov; 111(11):1186-1191. PubMed ID: 30838402
[TBL] [Abstract][Full Text] [Related]
11. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
12. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
Latimer NR; White IR; Abrams KR; Siebert U
Stat Methods Med Res; 2019 Aug; 28(8):2475-2493. PubMed ID: 29940824
[TBL] [Abstract][Full Text] [Related]
13. An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring.
Péron J; Buyse M; Ozenne B; Roche L; Roy P
Stat Methods Med Res; 2018 Apr; 27(4):1230-1239. PubMed ID: 27487842
[TBL] [Abstract][Full Text] [Related]
14. Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials?
Karrison T; Kocherginsky M
Clin Trials; 2018 Apr; 15(2):178-188. PubMed ID: 29502444
[TBL] [Abstract][Full Text] [Related]
15. Correcting the bias of the net benefit estimator due to right-censored observations.
Péron J; Idlhaj M; Maucort-Boulch D; Giai J; Roy P; Collette L; Buyse M; Ozenne B
Biom J; 2021 Apr; 63(4):893-906. PubMed ID: 33615533
[TBL] [Abstract][Full Text] [Related]
16. Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study.
Giai J; Maucort-Boulch D; Ozenne B; Chiêm JC; Buyse M; Péron J
Stat Med; 2021 Feb; 40(3):553-565. PubMed ID: 33140505
[TBL] [Abstract][Full Text] [Related]
17. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
18. Dynamic RMST curves for survival analysis in clinical trials.
Liao JJZ; Liu GF; Wu WC
BMC Med Res Methodol; 2020 Aug; 20(1):218. PubMed ID: 32854619
[TBL] [Abstract][Full Text] [Related]
19. Impact of correlations between prioritized outcomes on the net benefit and its estimate by generalized pairwise comparisons.
Fuyama K; Ogawa M; Mizusawa J; Kanemitsu Y; Fujita S; Kawahara T; Sakamaki K; Oba K
Stat Med; 2023 May; 42(10):1606-1624. PubMed ID: 36849124
[TBL] [Abstract][Full Text] [Related]
20. Restricted mean survival time for interval-censored data.
Zhang C; Wu Y; Yin G
Stat Med; 2020 Nov; 39(26):3879-3895. PubMed ID: 32767503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
